Stock SANA SANA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
5.51 USD +5.35% Intraday chart for Sana Biotechnology, Inc. -9.38% +35.05%
06-10 Transcript : Sana Biotechnology, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:40 PM
05-21 Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions
Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows
Sector Update: Health Care Stocks Edge Higher Premarket Friday
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing
Sana Biotechnology Says US FDA Approved Investigational New Drug Application to Launch Clinical Trial for SC262
Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262
Sana Biotechnology Insider Sold Shares Worth $300,098, According to a Recent SEC Filing
Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting
Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis
Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sana Biotechnology to Cut Spending on Fusogen Platform, Delaying SG299 IND; Workforce Slashed by 29%; Shares Rise
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SANA Stock
  4. News Sana Biotechnology, Inc.
  5. Other languages